| scholarly article | Q13442814 |
| P2093 | author name string | J R Harris | |
| M Mach | |||
| B Plachter | |||
| S Pepperl | |||
| J Münster | |||
| P2860 | cites work | CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma | Q24568172 |
| Vaccination against cytomegalovirus, the changeling demon | Q33605547 | ||
| Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates | Q33783800 | ||
| CpG motifs in bacterial DNA trigger direct B-cell activation | Q34307394 | ||
| Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. | Q34416715 | ||
| Acquisition of lymphokine-producing phenotype by CD4+ T cells | Q34724514 | ||
| Principles of cytomegalovirus antigen presentation in vitro and in vivo | Q35229535 | ||
| Proteins associated with purified human cytomegalovirus particles | Q35868126 | ||
| Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages | Q36327656 | ||
| Human CD8 transgene regulation of HLA recognition by murine T cells | Q36365522 | ||
| Cytomegalovirus proteins. I. Polypeptides of virions and dense bodies | Q36543853 | ||
| Nonviral microbodies with viral antigenicity produced in cytomegalovirus-infected cells | Q36590037 | ||
| Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. | Q36827278 | ||
| Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. | Q54290236 | ||
| Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. | Q54452849 | ||
| Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection | Q59057908 | ||
| The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection | Q67506329 | ||
| Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones | Q67518698 | ||
| Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression | Q67687100 | ||
| Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment | Q68263952 | ||
| Generation and application of a monoclonal antibody raised against a recombinant cytomegalovirus-specific polypeptide | Q68495145 | ||
| A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus | Q69349232 | ||
| Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus | Q70172856 | ||
| Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate | Q71568869 | ||
| Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor | Q72059554 | ||
| Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates | Q72154225 | ||
| Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice | Q72353217 | ||
| Prevention of transfusion-acquired cytomegalovirus infections in newborn infants | Q72879715 | ||
| Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine | Q72895264 | ||
| Humoral immune response to virions and dense bodies of human cytomegalovirus determined by enzyme immunofluorescence assay | Q72895352 | ||
| Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients | Q72930650 | ||
| Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group | Q73081680 | ||
| Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus | Q73378332 | ||
| Human cytomegalovirus matrix protein PP150 is efficiently presented as one of target antigens for cytotoxic T lymphocyte recognition | Q74568738 | ||
| Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients | Q77437131 | ||
| Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus | Q36867674 | ||
| Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus | Q36884645 | ||
| CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity | Q36919192 | ||
| Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes | Q37580704 | ||
| Impact of cytomegalovirus infection on organ transplant recipients | Q37897931 | ||
| The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation | Q38557888 | ||
| Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response | Q39427758 | ||
| Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes | Q39581864 | ||
| Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. | Q39595809 | ||
| Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport | Q39868792 | ||
| The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. | Q39876792 | ||
| A specific subform of the human cytomegalovirus transactivator protein pUL69 is contained within the tegument of virus particles. | Q39877419 | ||
| The morphogenesis of human cytomegalovirus. Isolation and polypeptide characterization of cytomegalovirions and dense bodies | Q39945396 | ||
| Human cytomegalovirus: glycoproteins associated with virions and dense bodies | Q40009723 | ||
| Human Cytomegalovirus: Purification of Enveloped Virions and Dense Bodies | Q40092439 | ||
| Selection of particles and proteins for use as human cytomegalovirus subunit vaccines | Q40142751 | ||
| Stimulation of human lymphocytes by cytomegalovirions and dense bodies | Q40191311 | ||
| T helper cell differentiation in immune response | Q40404872 | ||
| Role of cytokines in determining T-lymphocyte function | Q40626302 | ||
| Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. | Q40836115 | ||
| Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses | Q40880297 | ||
| Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes | Q41034377 | ||
| Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. | Q41091358 | ||
| Vaccines against human cytomegalovirus: time to test | Q41125679 | ||
| Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells | Q41179572 | ||
| Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response | Q41390404 | ||
| Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group | Q42666936 | ||
| Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex | Q42941471 | ||
| Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. | Q43745715 | ||
| Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers | Q44353347 | ||
| The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties | Q44586170 | ||
| Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group. | Q44822176 | ||
| Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies | Q44858818 | ||
| A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). | Q44862952 | ||
| Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization | Q44993083 | ||
| Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. | Q45084505 | ||
| Safety and immunogenicity of the Towne strain cytomegalovirus vaccine | Q45110668 | ||
| Hyperimmediate entry of human cytomegalovirus virions and dense bodies into human fibroblasts | Q45169992 | ||
| Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization | Q45747539 | ||
| Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load | Q45748608 | ||
| The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors | Q45797219 | ||
| Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial | Q45855440 | ||
| Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge | Q46111260 | ||
| A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein | Q46169855 | ||
| Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase | Q47752446 | ||
| Phagocytic processing of bacterial antigens for class I MHC presentation to T cells | Q50167043 | ||
| The outcome of congenital cytomegalovirus infection in relation to maternal antibody status | Q50539344 | ||
| The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro | Q52051964 | ||
| Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. | Q52116864 | ||
| The cytolytic T lymphocyte response to the murine cytomegalovirus. I. Distinct maturation stages of cytolytic T lymphocytes constitute the cellular immune response during acute infection of mice with the murine cytomegalovirus | Q52213413 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6132-6146 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression | |
| P478 | volume | 74 |
| Q27485181 | Activation of Virus-specific Memory B Cells in the Absence of T Cell Help |
| Q36645514 | Adenovirus E1A/E1B Transformed Amniotic Fluid Cells Support Human Cytomegalovirus Replication. |
| Q77358952 | An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA |
| Q78471193 | Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance |
| Q27026981 | Cell-mediated immunity to human CMV infection: a brief overview |
| Q37406553 | Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis |
| Q38791353 | Cytomegalovirus Vaccines: Current Status and Future Prospects. |
| Q37559627 | Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation |
| Q35917480 | Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy |
| Q33702990 | Cytomegalovirus vaccine development |
| Q37252609 | Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells |
| Q53648529 | Decreased serum level of antibody against human cytomegalovirus in patients with Beh�et?s disease |
| Q92689693 | Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response |
| Q37574334 | Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next? |
| Q36757818 | Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies |
| Q40629302 | Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles |
| Q34102747 | Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant |
| Q33843590 | Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). |
| Q40169615 | Human cytomegalovirus microRNAs are carried by virions and dense bodies and are delivered to target cells |
| Q47605886 | Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy |
| Q35965038 | Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. |
| Q34934444 | Is there a formula for an effective CMV vaccine? |
| Q40163004 | Modification of the HCMV-specific IFN-γ release test (QuantiFERON-CMV) and a novel proposal for its application |
| Q39960613 | Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83). |
| Q31104639 | Novel microneutralization assay for HCMV using automated data collection and analysis |
| Q44245356 | Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65. |
| Q39676490 | Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. |
| Q93080018 | Production Strategies for Pentamer-Positive Subviral Dense Bodies as a Safe Human Cytomegalovirus Vaccine |
| Q37409233 | Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers |
| Q38200419 | Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. |
| Q47115255 | Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection |
| Q34434818 | Progress toward an elusive goal: current status of cytomegalovirus vaccines |
| Q45858395 | Protein delivery by subviral particles of human cytomegalovirus |
| Q34349745 | Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases |
| Q37095341 | Recombinant viruses as tools to study human cytomegalovirus immune modulation |
| Q47867429 | Refinement of strategies for the development of a human cytomegalovirus dense body vaccine |
| Q41991559 | Subviral dense bodies of human cytomegalovirus stimulate maturation and activation of monocyte-derived immature dendritic cells. |
| Q36069582 | Synthetic DNA approach to cytomegalovirus vaccine/immune therapy |
| Q33551402 | Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge |
| Q90062901 | The Status of Vaccine Development Against the Human Cytomegalovirus |
| Q57038944 | The abundant tegument protein pUL25 of human cytomegalovirus prevents proteasomal degradation of pUL26 and supports its suppression of ISGylation |
| Q35143349 | The human cytomegalovirus. |
| Q42126964 | The tegument protein pp65 of human cytomegalovirus acts as an optional scaffold protein that optimizes protein uploading into viral particles. |
| Q34782568 | Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response |
| Q36839736 | Vaccine strategies against human cytomegalovirus infection. |
| Q38703173 | Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling |
Search more.